GLP-1 RA Therapy Slows Aortic Dilatation Progression in T2DM: Study

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-11-25 14:45 GMT | Update On 2025-11-26 06:38 GMT

A new study by Celestino Sardu and colleagues, published in the International Journal of Molecular Sciences (2025), has found that therapy with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may help slow the progression of ascending aortic dilatation in people with type 2 diabetes mellitus.

The research team followed adults with early-stage aortic enlargement and observed that those treated with GLP-1 RA medications-such as liraglutide, semaglutide, or dulaglutide-experienced slower structural changes in the aorta compared to individuals receiving standard diabetes care. This finding suggests that the cardiovascular benefits of GLP-1 RA therapy extend beyond blood sugar control, offering potential protective effects on large-vessel health.

The study explored how these medications might influence the underlying biology of aortic remodeling. Patients using GLP-1 RAs showed favorable changes in several vascular biomarkers, including reduced levels of inflammation and extracellular matrix breakdown.

These biological shifts point toward a mechanism in which GLP-1 RA therapy stabilizes the vascular wall and curbs progressive dilatation of the ascending aorta—a condition that, if left unchecked, can increase the risk of aneurysm and related complications. The researchers highlighted that this protective effect was independent of traditional cardiovascular risk factors or improvements in glucose metabolism, emphasizing a direct action on vascular tissue. What this means for diabetes management is significant.

The study adds to a growing body of evidence positioning GLP-1 RAs not only as glucose-lowering agents but as comprehensive metabolic and vascular protectants. For patients with type 2 diabetes who present with subclinical aortic changes, these drugs could play a role in reducing long-term cardiovascular risk. While larger multicenter trials are needed to confirm causality and guide clinical recommendations, the findings open new directions in diabetes care—where managing structural vascular health becomes as vital as controlling blood glucose.

Reference: Sardu, C., Marfella, L. V., Fumagalli, C., et al. (2025). GLP-1 receptor agonists are associated with reduced ascending aorta dilatation in patients with type 2 diabetes: A prospective study. International Journal of Molecular Sciences, 26(20), 9977.

Article Source : International Journal of Molecular Sciences

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Shravani Dali

Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

GLP-1 RA Therapy Slows Aortic Dilatation Progression in T2DM: Study

Similar News

Integrating Low-Cost Interventions: Yoga and Walking Demonstrate Significant Glycemic Benefit in Type 2 Diabetes

Incretin-Based Drugs Not Tied to Increased Risk of Acute Pancreatitis Among Diabetics: Study

Diabetes Worsens Survival Outcomes in Bladder Cancer Patients: Study

GLP-1 receptor agonists likely have little or no effect on obesity-related cancer risk: Study

Tirzepatide Linked to Lower Glaucoma Risk in Type 2 Diabetes Compared to Other Weight Loss Drugs: Study

Remedial action in first 2 years of diagnosis of prediabetes can Prevent Type 2 Diabetes, Indian Study Finds

GLP-1 Receptor Agonists Linked to Reduced Liver Cancer Risk in Type 2 Diabetes: Study

Saturated Fat Reduction: Mortality Benefit Limited to High-Risk Individuals, Claims Study